Patents Assigned to THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT
  • Systems and methods for recovery from motor control via stimulation to a substituted site to an affected area
    Patent number: 8388561
    Abstract: A device and methods for treating a subject with dysphagia or other neurological disease, neurological disorder, neurological injury, neurological impairment or neurodegenerative disease that affects voluntary motor control of the hyoid, pharynx, larynx, or oropharyngeal area is disclosed. A device of the invention generally comprises a vibrotactile stimulator for applying at least one stimulus to the outside surface of a subject's neck; a connector for attaching the vibrotactile stimulator to an outside surface of the subject's neck, and a switch control communicatively connected to the vibrotactile stimulator to selectively engage a manual stimulation module and/or automatic stimulation module. Stimulation of an outside surface of the throat area of a subject by a device of the invention stimulates a swallowing reflex in the subject.
    Type: Grant
    Filed: September 16, 2008
    Date of Patent: March 5, 2013
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Christy Ludlow, Newlin Morgan, George Dold, Soren Lowell, Katie Dietrich-Burns
  • Transcranial magnetic stimulation system and methods
    Patent number: 8388510
    Abstract: A system and methods for transcranial magnetic stimulation, the system including a helmet, a positioning portion, a stimulator and a cooling system, are disclosed. The helmet includes a coil for deep brain magnetic stimulation. The coil has a base portion, and return portions, which may include a protruding return portion and a contacting return portion. The coil is designed to minimize unintended stimulation of portions of the brain, while reducing accumulation of surface charges. The coil is stimulated at several locations and/or at different times so as to focus the electrical field on a specific deep neuronal structure.
    Type: Grant
    Filed: July 10, 2011
    Date of Patent: March 5, 2013
    Assignees: Brainsway, Inc., Yeda Research & Development Co. Ltd. at the Weizmann Institute of Science, The United States of America as Represented by the Secretary Department of Health and Human Services
    Inventors: Abraham Zangen, Yiftach Roth, Pedro C. Miranda, David Hazani, Mark Hallet
  • Methods, immunoassays and devices for detection of anti-lipoidal antibodies
    Patent number: 8389229
    Abstract: Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: March 5, 2013
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Arnold R. Castro, Robert W. George
  • Use of lymphocytes to measure anthrax lethal toxin activity
    Patent number: 8383359
    Abstract: It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4+ T-cell can be used to determine an amount of lymphocyte-associated anthrax lethal toxin activity present. Methods of using isolated lymphocytes to identify anthrax therapeutic agents and to determine the efficacy of a potential anthrax therapeutic are disclosed. Methods are also provided for diagnosing and treating anthrax infections.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: February 26, 2013
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: David M. Frucht, Hui Fang
  • Benztropine compounds and uses thereof
    Patent number: 8383817
    Abstract: Disclosed are benztropine analogs having the formula (I) in which Ar is a C6-C20 monocyclic aryl group or a C10-C20 bicyclic aryl group or a heteroaryl, heterocyclic, or arylheterocyclic group having 2 to 12 carbon atoms and one or more heteroatoms selected from the group consisting of N, O, S, P, and any combination thereof; m=1 to 5; n=1 to 3; and R1 to R4 are as described in the specification; or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical compositions and use thereof, e.g., in treating mental disorders.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: February 26, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Amy Hauck Newman, Mu-Fa Zou, Jonathan L. Katz
  • Aegyptin and uses thereof
    Patent number: 8383589
    Abstract: The present invention relates to the discovery of the Aegyptin gene and Aegyptin protein, a molecule that interacts with collagen and inhibits platelet adhesion, activation and aggregation. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: February 26, 2013
    Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Regents of the University of California
    Inventors: Eric Calvo, Osvaldo Marinotti, Jose M. C. Ribeiro, Ivo M. Francischetti
  • Adoptive cell therapy with young T cells
    Patent number: 8383099
    Abstract: The invention provides a method of promoting regression of a cancer in a mammal comprising (i) culturing autologous T cells; (ii) expanding the cultured T cells; (iii) administering to the mammal nonmyeloablative lymphodepleting chemotherapy; and (iv) after administering nonmyeloablative lymphodepleting chemotherapy, administering to the mammal the expanded T cells, wherein the T cells administered to the mammal are about 19 to about 35 days old and have not been screened for specific tumor reactivity, whereupon the regression of the cancer in the mammal is promoted.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: February 26, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Mark E. Dudley, Steven A. Rosenberg
  • Conjugates of surface proteins as malaria vaccines
    Patent number: 8383133
    Abstract: Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against Plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against Plasmodium vivax are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.
    Type: Grant
    Filed: October 15, 2007
    Date of Patent: February 26, 2013
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Rachel Schneerson, Joanna Kubler-Kielb, Yimin Wu, Louis Miller, Fathy D. Majadly, John B. Robbins
  • A3AR AGONISTS FOR THE TREATMENT OF UVEITIS
    Publication number: 20130045943
    Abstract: The present disclosure relates to the use of an A3AR agonist, such as IB-MECA, for the treatment or prevention of uveitis in a subject, as well as to methods for such treatment and pharmaceutical compositions comprising an amount of IB-MECA effective to treat uveitis.
    Type: Application
    Filed: February 27, 2011
    Publication date: February 21, 2013
    Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF
    Inventors: Rachel Caspi, Pnina Fishman
  • Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
    Patent number: 8378071
    Abstract: The disclosure provides antigenic peptides of Vascular Endothelial Growth Factor Receptor 2(VEGFR-2)/KDR. Pharmaceutical compositions including the peptides and/or antigen presenting cells that exhibit the VEGFR-2/KDR peptides on their cell surface are also provided. Methods for eliciting an immune response and for inhibiting angiogenesis by administering such pharmaceutical compositions are provided.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: February 19, 2013
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Samir N. Khleif, Yujun Dong
  • Non-invasive in vivo MRI axon diameter measurement methods
    Patent number: 8380280
    Abstract: Magnetic resonance methods include modeling magnetic resonance signals obtained from specimens at low and high q-values to obtain parameters and distributions of parameters associated with specimen structure and orientation. In evaluation of brain white matter specimens, diffusion within axons can be modeled based on hindered diffusion parallel to an axis of the axon and restricted diffusion perpendicular to the axis. Diffusion exterior to axons can be modeled as hindered diffusion with differing diffusivities parallel to and perpendicular to the axis. Based on extracted parameters and associated model functions, distributions of specimen properties such as intra and extra-axonal principal diffusivities and the corresponding principal directions can be estimated. Features of the axon diameter distribution can also be estimated using this approach.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: February 19, 2013
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Peter J. Basser, Yaniv Assaf
  • BETA-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY
    Publication number: 20130039886
    Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.
    Type: Application
    Filed: March 11, 2011
    Publication date: February 14, 2013
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, The University of Birmingham, of Edgbaston
    Inventors: Jay A. Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr Illarionov, Gurdyal S. Besra
  • THERAPEUTIC APPLICATIONS OF FATTY ACID AMIDE HYDROLASE INHIBITORS
    Publication number: 20130041037
    Abstract: Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of oleamide (an endogenous sleep-inducing lipid) and anandamide (an endogenous ligand for cannabinoid receptors). Disclosed herein are potent inhibitors of FAAH and methods for their use for treating a variety of disorder, including hypertension and cardiac hypertrophy.
    Type: Application
    Filed: October 15, 2012
    Publication date: February 14, 2013
    Applicants: Alexandros Makriyannis, The United States of America as represented by the Secretary, Department of Health and Human Service
    Inventors: George Kunos, Alexandros Makriyannis
  • Recovery of recombinant human parainfluenza virus type 2 (HYPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
    Patent number: 8367074
    Abstract: Recombinant human parainfluenza virus type 2 (HPIV2) viruses and related immunogenic compositions and methods are provided. The recombinant HPIV2 viruses, including HPIV2 chimeric and chimeric vector viruses, provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic compositions for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV2 genome or antigenome.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: February 5, 2013
    Assignee: The United States of America as represented by the Secretary of the Department of Health & Human Services
    Inventors: Mario H. Skiadopoulos, Brian R. Murphy, Peter L. Collins
  • Thermal inactivation of rotavirus
    Patent number: 8357525
    Abstract: Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: January 22, 2013
    Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Baoming Jiang, Roger I. Glass, Jean-Francois Saluzzo
  • Primers and probes for the detection of
    Patent number: 8357488
    Abstract: Methods of detecting Streptococcus pneumoniae (S. pneumoniae), are disclosed. A sample suspected of containing a nucleic acid of S. pneumoniae is screened for the presence or absence of that nucleic acid. The presence of the S. pneumoniae nucleic acid indicates the presence of S. pneumoniae. Determining whether the S. pneumoniae nucleic acid is present in the sample can be accomplished by detecting hybridization between a S. pneumoniae probe, such as a S. pneumoniae lytA probe, a S. pneumoniae psaA probe, or a S. pneumoniae ply probe. Probes and primers for the detection of S. pneumoniae are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: January 22, 2013
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Lesley McGee, Maria Lucia Tondella, Maria da Gloria Siqueira Carvalho
  • Human anti-mesothelin monoclonal antibodies
    Patent number: 8357783
    Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human mesothelin with a binding affinity of about 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human mesothelin in a sample. Methods of diagnosing cancer, or confirming a diagnosis of cancer, are disclosed herein that utilize these antibodies. Methods of treating a subject with cancer are also disclosed.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: January 22, 2013
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Yang Feng, Ira H. Pastan
  • CD40 ligand adjuvant for respiratory syncytial virus
    Patent number: 8354115
    Abstract: The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a CD40L coding region. The enhanced immune response produced by the adjuvants and methods of the current invention includes both increased expression of Th1 cytokines and increased production of antibody.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: January 15, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Ralph A. Tripp, Larry J. Anderson, Michael P. Brown
  • METHODS FOR DETECTING ADHD SUSCEPTIBILITY AND PREDICTING SEVERITY AND LONG TERM OUTCOME OF ADHD SYMPTOMS
    Publication number: 20130012497
    Abstract: The invention provides methods of determining an altered susceptibility to develop ADHD, methods of predicting or determining the severity of symptoms of ADHD and associated disorders, and methods of treatment based on the presence or absence of one or more alleles of single nucleotide polymorphism (SNP) markers.
    Type: Application
    Filed: May 18, 2012
    Publication date: January 10, 2013
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Ser.
    Inventors: Maximilian Muenke, Mauricio Arcos-Burgos, Maria Teresa Acosta
  • Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury
    Patent number: 8349888
    Abstract: The present invention provides compositions and methods for the prophylactic and therapeutic treatment of animals, including humans from radiation injury. In particular, the present invention provides methods and compositions comprising the isoflavone genistein (4?,5,7-trihydroxyflavone) or phytoestrogenic isoflavonoids.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: January 8, 2013
    Assignees: The United States of America as represented by the Secretary Department of Health and Human Services, Henry M. Jackson Foundation for the Advancement of Military Medicine
    Inventors: Michael R. Landauer, Thomas Michael Seed, Venkataraman Srinivasan, Alla Shapiro, Chris H. Takimoto